Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2004;2004(1):CD003918.
doi: 10.1002/14651858.CD003918.pub2.

Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix

P Symonds  1 , J Kirwan, C Williams, C Humber, J Tierney, J Green, M Collingwood
Affiliations
Meta-Analysis

Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix

P Symonds et al. Cochrane Database Syst Rev. 2004.

Abstract

Background: A number of randomised studies suggest hydroxyurea given alongside radiotherapy improves survival in patients with locally advanced cervix cancer. Following publication of five large randomised trials in 1999 and 2000 concomitant chemoradiotherapy has become standard treatment for these patients. In two of the studies hydroxyurea was given to patients in both control and experimental arms. The precise role of this orally administered cytotoxic drug is not known.

Objectives: To assess the effectiveness (survival and toxicity) of concomitant radiation and hydroxyurea compared with radiotherapy alone in treating locally advanced cervix cancer.

Search strategy: We searched the following:Cochrane Gynaecological Cancer Group's Specialised RegisterCENTRAL (Cochrane Library on CD ROM, issue 4, 2002) MEDLINE (Silver Platter, from 1970 to 2001) EMBASE (from 1980 to 2001) CANCERLIT (from 1970 to 2001) PDQ (search for open and closed trials) LILACSMeta-register (ongoing trials)Searches were not language or publication restricted. Investigators of relevant trials were contacted for further information.

Selection criteria: Randomized controlled trials comparing concomitant radiotherapy (+/- surgery) with hydroxyurea versus radiotherapy (+/- surgery) for locally advanced cervix cancer.

Data collection and analysis: Two authors independently reviewed trials for inclusion and extracted data. Discussions on all aspects of data collection and analysis took place among all the authors at regular intervals.

Main results: Seven studies were found to be suitable for inclusion from 33 identified as relevant. None of the trials provided adequate evidence to support the use of hydroxyurea owing to small sample size, large numbers of post-randomisation exclusions and questionable rules for censoring, particularly a failure to include treatment-related deaths in the survival analysis. Details of statistical analysis were limited and often confusing, and we felt meta-analysis would lead to unreliable and invalid conclusions. Most studies appeared to be double blind placebo-controlled studies but none give details of power calculations or reasons for stopping recruitment. Only two studies had more than 50 patients. Patients were excluded from analysis in most trials for treatment-related reasons; in one, less than half those recruited were used in the analysis, the remainder having been excluded because of tumour progression or treatment-related conditions e.g. septicaemia, worsening renal/hepatic function. In another trial five out of 20 in the hydroxyurea group died of treatment-related complications but the five-year survival group was presented as 94%.

Reviewer's conclusions: We found no evidence to support the use of hydroxyurea in addition to radiotherapy in the routine treatment of cervix cancer.

PubMed Disclaimer

Conflict of interest statement

None known

Update of

  • doi: 10.1002/14651858.CD003918

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Hreshchyshyn 1979 {published data only}
    1. Hreshchyshyn MM, Aron BS, Boronow RC, Franklin EW, Shingleton HM, Blessing JA. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. International Journal of Radiation Oncology, Biology, Physics 1979;5:317‐22. - PubMed
Madoc‐Jones 1980 {published data only}
    1. Madoc JH, Perez C, Camel M, Jennings F. Preliminary experience in a prospective randomized trial to assess the value of hydroxyurea in addition to conventional radiotherapy in the management of advanced stages of carcinoma of the uterine cervix. International Journal of Radiation Oncology, Biology, Physics 1980;6(10):1430. [EMBASE 1981119496]
Piver 1974 {published data only}
    1. Piver MS, Barlow JJ, Vongtama V, Webster J. Hydroxyurea and radiation therapy in advanced cervical cancer. American Journal of Obstetrics and Gynecology 1974;120(7):969‐72. - PubMed
Piver 1977 {published data only}
    1. Piver MS, Barlow JJ, Vongtama V, Blumenson L. Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. American Journal of Obstetrics and Gynecology 1977;129(4):379‐83. [MEDLINE: ] - PubMed
Piver 1983 {published data only}
    1. Piver MS, Barlow J, Vongtama V, Blumenson L. Hydroxyurea: A radiation potentiator in carcinoma of the uterine cervix. American Journal of Obstetrics and Gynecology 1983;147(7):803‐8. - PubMed
Piver 1987 {published data only}
    1. Piver MS, Vongtama V, Emrich LJ. Hydroxyurea plus pelvic radiation versus placebo plus pelvic radiation in surgically staged stage IIIB cervical cancer. Journal of Surgical Oncology 1987 Jun;35(2):129‐34. [PMID 3108586] - PubMed
Piver 1989 {published data only}
    1. Piver M, Khalil M, Emrich LJ. Hydroxyurea plus pelvic irradiation versus placebo plus pelvic irradtiation in nonsurgically staged stage IIIB cervical cancer. Journal of Surgical Oncology 1989 Oct;42(2):120‐5. [PMID 2796346] - PubMed

References to studies excluded from this review

Stehman 1988 {published data only}
    1. Stehman FB, Bundy BN, Keys H, Currie JL, Mortel R, Creasman WT. A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix. A preliminary report of a Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology 1988;159(1):87‐94. - PubMed
Stehman 1993 {published data only}
    1. Stehman FB, Bundy BN, Thomas G, Keys HM, d'Ablaing III G, Fowler Jr WC, Mortel R, Creasman WT. Hydroxyurea Versus Misonidazole With Radiation in Cervical Carcinoma: Long‐Term Follow‐Up of a Gynecologic Oncology Group Trial. Journal of Clinical Oncology 1993;11(8 (August)):1523‐8. - PubMed
Stehman 1993a {published data only}
    1. Stehman FB, Bundy BN. Carcinoma of the Cervix Treated with Chemotherapy and Radiation Therapy. Cancer Supplement 1993;71(4):1697‐701. - PubMed

Additional references

Altman 1991
    1. Altman DG. Randomisation. British Medical Journal 1991;302:1481‐2. - PMC - PubMed
Beitler 2002
    1. Beitler JJ, Anderson P, Haynes H, Sood B, Fields A, Goldberg G, Vikram B, Runowicz CD, Wadler S. Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para‐aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of theuterine cervix. International Journal of Radiation Oncology, Biology, Physics 2002;52(3):637‐42. - PubMed
Benedet 1998
    1. Benedet J, Odicino F, Maisonneuve P, Severi G, Creasman W, Shepherd J, Sideri M, Pecorelli S. FIGO 90‐92 Annual Report. Journal of Epidemiology and Biostatistics 1998;3(1):1‐34.
Cannistra 1996
    1. Cannistra SA, Niloff JM. Cancer of the uterine cervix. The New England Journal of Medicine 1996;334(16):1030‐8. - PubMed
Cochrane Handbook
    1. Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.1.5 [updated April 2002]. In: The Cochrane Library [database on CDROM], Issue 2, 2002. Oxford: Update Software. Updated quarterly.
Coia L 1990
    1. Coia L, Won M, Laniano R, et al. The patterns of care outcome study for cancer of the uterine cervix: results of the second national practice survey. Cancer 1990;66:2451‐6. - PubMed
Cook 1984
    1. Cook GA, Draper GJ. Trends in cervical cancer and carcinoma in situ in Great Britain. British Journal of Cancer 1984;50:367‐75. - PMC - PubMed
Day 1984
    1. Day NE. Effect of cervical screening in Scandinavia. Obstetrics and Gynecology 1984;63:714‐8. - PubMed
Devesa 1995
    1. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF. Recent cancer tends in the United States. Journal of the National Cancer Institute 1995;87(3):175‐82. - PubMed
Eifel 1997
    1. Eifel PJ, Berek JS, Thigpen JT. Gynecologic Cancers. Section 2. Cancer of the cervix, vagina, vulva. In: DeVita VT, Jr, Hellman S, Rosenberg SA editor(s). Cancer: Principles & Practice of Oncology. Fifth. Philadelphia: Lippincott‐Raven, 1997:1427‐78.
Green 2005
    1. Green J, Kirwan J, Tierney J, Symonds P, Fresco L, Williams C, Collingwood M. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD002225] - DOI - PMC - PubMed
Lachin 2000
    1. Lachin JM. Statistical considerations in the intent‐to‐treat principle. Controlled Clinical Trials 2000;21:167‐89. - PubMed
Landoni 1997
    1. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C. Randomised study of radical surgery versus radiotherapy for stage Ib‐IIa cervical cancer. Lancet 1997;350:535‐40. - PubMed
Omura 1996
    1. Omura GA. Chemotherapy for stage IVB or recurrent cancer of the uterine cervix. Journal of the National Cancer Institute 1996;21:123‐6. - PubMed
Phillips 1966
    1. Phillips RA, Tolmach LJ. Repair of potentially lethal damage in X‐irradiated HeLa cells. Radiation Research 1966 Nov;29(3):413‐32. [PMID: 4224300] - PubMed
Pisani 1999
    1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. International Journal of Cancer 1999;83:18‐29. - PubMed
Pisani 2002
    1. Pisani P, Bray F, Parkin DM. Estimates of the world‐wide prevalence of cancer for 25 sites in the adult population. International Journal of Cancer 2002 Jan 1;97(1):72‐81. - PubMed
Schulz 2002
    1. Schulz KF, .Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and the lost and the wayward. Lancet 2002;359:781‐5. - PubMed
Sinclair 1968
    1. Sinclair WK. The combined effect of hydroxyurea and x‐rays on Chinese hamster cells in vitro. Cancer Research 1968 Feb;28(2):198‐206. [PMID: 5641513] - PubMed
Thigpen 1995
    1. Thigpen JT, Vance R, Puneky L, Khansur T. Chemotherapy as a Palliative Treatment in Carcinoma of the Uterine Cervix. Seminars in Oncology 1995;22(2 (Suppl 3 April)):16‐24. - PubMed
Tierney 1999
    1. Tierney JF, Stewart LA, Parmar MKB. Can the published data tell us about the effectiveness of neoadjuvant chemotherapy for locally advanced cancer of the uterine cervix?. European Journal of Cancer 1999;35(3):406‐9. - PubMed
Wallner 1987
    1. Wallner KE, Li GC. Effect of cisplatin resistance on cellular radiation response. International Journal of Radiation Oncology, Biology, Physics 1987;13:587‐91. - PubMed
Whitney 1999
    1. Whitney CW, Sauser W, Bundy BN, Malfetano JH, Hannigan EV, Fowler Jr WC, Clarke‐Pearson DL, Liao S‐Y. Randomised comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB/IVA in carcinoma of the cervix with negative lymph nodes: a Gynecologic Oncology and Southwest Oncology Group study. Journal of Clinical Oncology 1999;17:1339‐48. - PubMed

MeSH terms